Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cyclosporin or tacrolimus · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Cyclosporin or tacrolimus | DRUG | - |
Inclusion Criteria: * Age over 18 * Treatment with a calcineurin inhibitor * Patients with mild to moderate renal insufficiency Exclusion Criteria: * Patients with acute rejection * Patients who received a transplant more than 10 years ago
Cyclosporin or tacrolimus is used for graft rejection in patients who have undergone kidney transplantation. It is being studied in the context of kidney failure and kidney transplantation to manage the immune response and prevent organ rejection.
Cyclosporin or tacrolimus is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
Cyclosporin or tacrolimus is in Phase 3 clinical development. It is an investigational small molecule being evaluated for graft rejection, and it is not yet approved for this use.
Cyclosporin or tacrolimus is associated with one completed Phase 3 clinical trial, NCT00273871, titled 'Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients.' The trial enrolled 190 participants.
Cyclosporin or tacrolimus is not the same as Rapamune. The clinical trial NCT00273871 compares conversion from calcineurin inhibitors, which include cyclosporin and tacrolimus, to Rapamune versus standard therapy in kidney transplant recipients.